<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04868188</url>
  </required_header>
  <id_info>
    <org_study_id>136965 V1.0</org_study_id>
    <nct_id>NCT04868188</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Voriconazole in Adult ECMO Patients</brief_title>
  <official_title>An Observational Pharmacokinetic Study of Intravenous Voriconazole Used for Treatment of Invasive Aspergillosis in Adult Patients With Severe Influenza / COVID-19 Supported With Extra-corporeal Membrane Oxygenation (ECMO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals, Leicester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospitals, Leicester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given the high burden of fungal co-infection in patients admitted to ICU and improved&#xD;
      outcomes with prompt anti-fungal treatment, it is of vital importance that the doses of&#xD;
      anti-fungal are optimum to improve the dismal outcome of influenza/Covid-19 Associated&#xD;
      Pulmonary Aspergillosis.&#xD;
&#xD;
      Due to the reported difficulties in dosing appropriately in ECMO patients, a prospective&#xD;
      observational study is required to accurately evaluate the pharmacokinetics of voriconazole&#xD;
      in patients supported on ECMO. This is to ensure that the dose of voriconazole is optimised&#xD;
      to improve efficacy and reduce toxicity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single centre, open label, prospective, observational, pharmacokinetic study of&#xD;
      voriconazole administered to adults (aged &gt; 18 years) supported on ECMO. This is a&#xD;
      low-interventional study. There will be no treatment changes as a result of participation in&#xD;
      this study. The decision to initiate voriconazole therapy will be taken independent of this&#xD;
      study protocol. Intravenous voriconazole will be prescribed according to the approved dose in&#xD;
      the SmPC. All adults requiring voriconazole therapy will be eligible for recruitment into the&#xD;
      study.&#xD;
&#xD;
      The only additional procedure in this study will be to take a total of 5 blood samples across&#xD;
      3 occasions/sampling windows (Day 1-4, Day 6-9 and Day 11-14) to determine plasma&#xD;
      concentrations of voriconazole. In addition, a single buccal swab to determine the CYP2C19&#xD;
      genotype will be undertaken during the course of ICU stay.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 24, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma levels of voriconazole administered to critically ill adult patients with suspected fungal disease, receiving ECMO support.</measure>
    <time_frame>14 days</time_frame>
    <description>Primary parameter: Clearance (CL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma levels of voriconazole administered to critically ill adult patients with suspected fungal disease, receiving ECMO support.</measure>
    <time_frame>14 days</time_frame>
    <description>Primary parameter: Volume of distribution (V)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma levels of voriconazole administered to critically ill adult patients with suspected fungal disease, receiving ECMO support.</measure>
    <time_frame>14 days</time_frame>
    <description>Secondary parameters: Maximum plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma levels of voriconazole administered to critically ill adult patients with suspected fungal disease, receiving ECMO support.</measure>
    <time_frame>14 days</time_frame>
    <description>Secondary parameters: Area under plasma concentration time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma levels of voriconazole administered to critically ill adult patients with suspected fungal disease, receiving ECMO support.</measure>
    <time_frame>14 days</time_frame>
    <description>Secondary parameters: Half-life (t1/2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the influence of CYP2C19 genotype on the plasma levels of voriconazole</measure>
    <time_frame>14 days</time_frame>
    <description>CYP2C19 genotype: identify *2, *3, and *17 mutations and any influence on plasma levels of voriconazole</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Aspergillosis</condition>
  <condition>Influenza</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Voriconazole administration to adult patients with suspected fungal disease, receiving ECMO support</arm_group_label>
    <description>Adult (&gt;18 years) patients with severe influenza / Covid-19 supported on ECMO and with confirmed or suspected aspergillosis infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>5 blood samples</intervention_name>
    <description>5 blood samples across 3 occasions/sampling windows (Day 1-4, Day 6-9 and Day 11-14) to determine plasma concentrations of voriconazole</description>
    <arm_group_label>Voriconazole administration to adult patients with suspected fungal disease, receiving ECMO support</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Determination of CYP2C19 genotype</intervention_name>
    <description>A single buccal swab to determine the CYP2C19 genotype will be undertaken during the course of ICU stay.</description>
    <arm_group_label>Voriconazole administration to adult patients with suspected fungal disease, receiving ECMO support</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients (≥18 years) with acute (cardio-)respiratory failure, inadequately supported&#xD;
        by mechanical ventilation, requiring additional support with ECMO, and in the opinion of&#xD;
        the direct care team requires intravenous voriconazole therapy for treatment of confirmed&#xD;
        or suspected invasive aspergillosis, will be eligible to be recruited.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults aged ≥18 years&#xD;
&#xD;
          2. Admitted to ICU on ECMO support&#xD;
&#xD;
          3. Positive influenza or SARS-CoV-2 PCR from nasal, throat swab, BAL or other respiratory&#xD;
             specimen.&#xD;
&#xD;
          4. Positive invasive aspergillosis infection (positive Aspergillus species culture from&#xD;
             respiratory specimen or positive serum galactomannan) or strong clinical suspicion of&#xD;
             invasive aspergillosis infection based on symptoms, CT, CXR.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No participants &lt; 18 years of age&#xD;
&#xD;
          2. Not requiring ECMO support&#xD;
&#xD;
          3. No positive influenza or SARS-CoV-2 results&#xD;
&#xD;
          4. Any other significant disease or disorder which, in the opinion of the Investigator,&#xD;
             may either put the participants at risk because of participation in the trial, or may&#xD;
             influence the result of the trial, or the participant's ability to participate in the&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hakeem Yusuff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals, Leicester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hakeem Yusuff, MD</last_name>
    <phone>07789 880920</phone>
    <email>hakeem.yusuff@uhl-tr.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hussain Mulla, PhD</last_name>
    <phone>07702 559537</phone>
    <phone_ext>2708</phone_ext>
    <email>hussain.mulla@uhl-tr.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals of Leicester</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hakeem Yusuff</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Voriconazole</keyword>
  <keyword>Extracorporeal Membrane Oxygenation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

